Vaxart (VXRT) Expected to Announce Quarterly Earnings on Monday

Vaxart (NASDAQ:VXRT - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.05. The company had revenue of $15.19 million during the quarter, compared to analysts' expectations of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Stock Performance

Shares of NASDAQ VXRT traded up $0.01 during mid-day trading on Friday, reaching $0.42. 736,199 shares of the company traded hands, compared to its average volume of 2,412,311. The company's fifty day moving average is $0.42 and its two-hundred day moving average is $0.59. Vaxart has a fifty-two week low of $0.29 and a fifty-two week high of $1.07. The stock has a market cap of $95.82 million, a PE ratio of -1.02 and a beta of 1.27.

Wall Street Analyst Weigh In

Separately, B. Riley dropped their price target on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.